Carvedilol

證據等級: L5

預測適應症: 10 個

Carvedilol: From Heart Failure to Chronic Pulmonary Heart Disease

One-Sentence Summary

Carvedilol is a non-selective β-adrenergic and α1-adrenergic blocker established in clinical practice for chronic heart failure, hypertension, and post-myocardial infarction left ventricular dysfunction. The TxGNN model identified 10 new predicted indications; the most evidence-supported candidate is Chronic Pulmonary Heart Disease (cor pulmonale) (TxGNN rank #6), with 12 registered clinical trials and 20 publications — including 4 Grade-A trials directly studying Carvedilol in this population — currently backing this direction.

Quick Overview

Item	Content
Original Indication	Chronic heart failure, hypertension, post-MI left ventricular dysfunction
Predicted New Indication	Chronic Pulmonary Heart Disease (Cor Pulmonale)
TxGNN Prediction Score	94.55%
Evidence Level	L3
Singapore Market Status	Not registered
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Carvedilol is a third-generation beta-blocker with a uniquely broad pharmacological profile. Unlike cardioselective agents such as bisoprolol or metoprolol, it simultaneously blocks β1-, β2-, and α1-adrenergic receptors, and additionally exerts potent antioxidant activity through its carbazole moiety. The α1-blocking component reduces systemic and pulmonary vascular resistance — a property not shared by most beta-blockers — making it pharmacologically distinctive among its class. Although the full MOA data from DrugBank is currently unavailable, its established mechanism in heart failure is well-characterised in the published literature: it slows pathological cardiac remodelling (via β1-blockade) and reduces afterload (via α1-blockade), with the antioxidant activity adding an additional layer of cardioprotection.

Chronic pulmonary heart disease (cor pulmonale) is fundamentally a right heart failure syndrome driven by chronic pulmonary disease, most often COPD. The core pathophysiology — right ventricular pressure overload, adverse remodelling, oxidative stress from chronic hypoxia — maps directly onto the mechanisms Carvedilol already targets in left-sided heart failure. Its α1-blockade may lower pulmonary vascular resistance, its β1-blockade can attenuate maladaptive right ventricular remodelling, and its antioxidant action may mitigate COPD-driven oxidative injury. This multi-point mechanistic overlap provides a credible biological rationale for the TxGNN prediction.

The primary safety concern is non-selective β2-blockade, which can worsen bronchospasm in patients with underlying airway disease. This risk is real, and several of the supporting trials were specifically designed to evaluate it. Crucially, multiple Danish and Italian register-based cohort studies — along with Phase 4 randomised crossover trials — have demonstrated that Carvedilol can be used safely in patients with concurrent heart failure and COPD when dose titration is careful and pulmonary function is monitored. This body of evidence differentiates the cor pulmonale prediction from the other TxGNN candidates (ranks 1–5 and 7–10), which either lack any supporting data (L5, Hold) or have mechanistic arguments against Carvedilol use.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02120339	Phase 1	Terminated	5	Pilot study of chronic Carvedilol in pulmonary arterial hypertension (PAH) — assessed RV function and safety; terminated early due to safety concerns. The only dedicated Carvedilol-in-PAH trial; critical for safety profiling in pulmonary hypertensive populations.
NCT00517725	Phase 4	Completed	60	Three-arm head-to-head trial: Nebivolol vs Bisoprolol vs Carvedilol in heart failure patients. Primary endpoints include exercise capacity, chemoreceptor response, and pulmonary function under normoxic and hypoxic conditions. Carvedilol is an explicit trial arm with lung function as a key endpoint.
NCT03370835	Phase 4	Completed	21	Randomised open-label crossover: Metoprolol succinate-ER vs Carvedilol in COPD patients — directly evaluates tolerability of a non-selective beta-blocker in the chronic pulmonary heart disease population at guideline-recommended doses.
NCT00924833	Phase 4	Completed	27	Carvedilol vs Nebivolol cardiovascular, metabolic, and respiratory effects at high altitude — a validated physiological model for hypoxic cardiopulmonary stress that mimics chronic heart failure with hypoxia.
NCT01656005	Phase 4	Completed	18	Chronic dose exposure to cardioselective vs non-cardioselective beta-blockers (Carvedilol class) in moderate-to-severe COPD — assesses cardiopulmonary function over sustained exposure.
NCT00384566	Phase 4	Withdrawn	0	CAMERA Study: purpose-designed Carvedilol vs Metoprolol respiratory assessment in CHF patients — highest scientific relevance, but withdrawn before enrolment. No usable data; highlights the unmet evidence gap.
NCT00292162	N/A	Completed	41	Radiofrequency ablation for atrial fibrillation in advanced CHF; Carvedilol used as background medication, not the study intervention. Low direct relevance.
NCT00878384	N/A	Completed	52	AF catheter ablation vs rate-control in CHF; does not address chronic pulmonary heart disease as a primary endpoint. Low relevance.
NCT03778554	Phase 4	Active, not recruiting	2760	DANBLOCK: long-term beta-blocker after MI in patients with preserved ejection fraction; population (post-MI, no HF) differs substantially from cor pulmonale. Low relevance.
NCT06697353	N/A	Completed	4936	ROVER Japan: real-world Vericiguat outcomes in HFrEF; Carvedilol is background therapy only, no cor pulmonale-specific analysis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20413026	2010	Randomised Crossover	JACC	Randomised crossover comparing β1-selective vs non-selective (Carvedilol) agents in CHF+COPD patients; directly measures respiratory, haemodynamic, and clinical effects of switching between drug types.
22015086	2011	RCT	Respiratory Medicine	Randomised trial: Bisoprolol vs Carvedilol in HF+COPD — compares pulmonary function, exercise tolerance, and hospitalisation risk between the two most commonly used beta-blockers in this comorbid population.
31391573	2019	Register Cohort	Scientific Reports	Italian register study: predictors of Carvedilol choice in HF+COPD patients; guidelines favour cardioselective agents, yet real-world Carvedilol prescribing remains high, suggesting perceived clinical utility.
32000982	2020	Propensity-Matched Cohort	Am J Cardiology	Metoprolol vs Carvedilol in elderly patients with HF+COPD+DM+renal failure using Danish national registers (1:1 propensity match); 1-year survival and disease-specific hospitalisation outcomes.
29159953	2018	Nationwide Cohort	Eur J Heart Failure	Danish nationwide cohort: Carvedilol vs metoprolol/bisoprolol/nebivolol in HF+COPD — compared COPD-related hospitalisation hazard and beta-blocker persistence in the real-world setting.
26844454	2016	Population Cohort	Medicine	Taiwan NHI database: Carvedilol, Bisoprolol, and Metoprolol survival effects in coexistent HF+COPD; largest Asian population-based analysis of this three-way comparison, directly relevant to Singapore practice.
12490274	2002	Prospective Cohort	J Heart Lung Transplant	Prospective evaluation of Carvedilol tolerability and efficacy in CHF patients with concomitant COPD or asthma — foundational safety dataset demonstrating acceptable lung function outcomes with careful titration.
31521680	2019	State-of-the-Art Review	JACC Heart Failure	Comprehensive review of diagnostic and therapeutic gaps in HF+COPD; summarises current evidence for beta-blocker use including Carvedilol, spirometry underutilisation, and guideline-practice gaps.
18294490	2008	Epidemiology	Am Heart Journal	Prevalence and prognostic impact of COPD in stable HF — establishes the size of the cor pulmonale comorbidity burden and documents beta-blocker withdrawal patterns by COPD status.
15358010	2004	Review	JACC	Therapeutic update specifically on non-selective β- and α-adrenergic blockade (Carvedilol's precise profile) in coexistent CHF+COPD — mechanistic rationale and clinical management guidance.

Singapore Market Information

Carvedilol is currently not registered with the Health Sciences Authority (HSA) in Singapore. No product licences are on record.

For clinical research use in Singapore, importation under the HSA Special Access Route (SAR) or a Clinical Trial Authorisation (CTA) framework would be required before any investigator-initiated trial could proceed.

Safety Considerations

Detailed safety data from the Singapore HSA package insert and DrugBank were not available for this analysis (flagged as data gaps requiring remediation). Based on well-established pharmacological class knowledge:

Bronchospasm risk: Non-selective β2-adrenergic blockade is the most clinically important concern in this indication. In patients with underlying airway obstruction (the defining feature of cor pulmonale aetiology), Carvedilol may precipitate or worsen bronchoconstriction. Mandatory slow titration from the lowest available dose is essential, and FEV1/SpO2 monitoring should be incorporated into any study protocol.
Haemodynamic effects: Combined α1 and β-blockade can produce significant bradycardia and hypotension, particularly at initiation or during dose escalation in already-compromised right heart failure patients.

Please refer to the originator package insert for complete contraindications, drug interactions, and special population guidance. Remediation of the TFDA/HSA package insert data gap (flagged as Blocking severity) is required before any formal safety screening.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 4 randomised crossover trials and large propensity-matched cohort studies directly evaluate Carvedilol in patients with heart failure concurrent with chronic pulmonary disease — the pathophysiological substrate of cor pulmonale. The mechanistic rationale (right ventricular remodelling via β1-blockade, pulmonary afterload reduction via α1-blockade, oxidative injury mitigation via antioxidant activity) is well-grounded and directly maps to cor pulmonale pathophysiology. The evidence base, while not yet Phase 3 RCT-level for this specific indication, is sufficient to support a structured research programme with appropriate safety monitoring.

To proceed, the following is needed:

Remediate the Blocking data gap: obtain and parse the TFDA/HSA package insert to extract key warnings and contraindications before any formal safety evaluation
Retrieve full MOA data from DrugBank to complete the mechanistic linkage analysis
Obtain a drug interaction profile against common COPD co-medications (long-acting bronchodilators, inhaled corticosteroids, theophylline)
Design a dedicated Phase 2 RCT in confirmed cor pulmonale patients — existing evidence derives from HF+COPD cohorts without verified cor pulmonale diagnosis; bridging data are needed
Define a pulmonary function monitoring plan (FEV1/FVC, SpO2, 6-minute walk test) as mandatory safety endpoints for any trial protocol
Initiate HSA Special Access Route (SAR) or CTA application given the absence of Singapore market registration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.